Follow The Filings

RLMD Relmada Therapeutics Inc.

Health Care, filed as RELMADA THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.6%
  • $6.5M

Who owns this now

Largest portfolio weights among holders, up to 0.6% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman 0.59%

Who owns RLMD

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.59% Hold 935,000 $6.5M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RLMD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RLMD insider trades
  • $4M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Maged Shenouda CFO
    Buy
    $844K 200,000 shares at $4.22 +25% to stake
    Traded Sep 9–10 Filed Sep 11
    ↗
  2. Sergio Traversa CEO
    Buy
    $828K 200,000 shares at $4.14 +15% to stake
    Traded Sep 9–10 Filed Sep 11
    ↗
  3. Sergio Traversa CEO
    Buy
    $113K 27,500 shares at $4.12 +2.2% to stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
    ↗
  4. Maged Shenouda CFO
    Buy
    $48K 11,665 shares at $4.12 +1.5% to stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
    ↗
  5. Chuck Ence COO
    Buy
    $299K 136,000 shares at $2.20 +51% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗
  6. Sergio Traversa CEO
    Buy
    $600K 272,500 shares at $2.20 +27% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗
  7. Maged Shenouda CFO
    Buy
    $1.1M 500,000 shares at $2.20 +173% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗
  8. Paul Edward Kelly COO
    Buy
    $198K 90,000 shares at $2.20 +22% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A PROXY STATEMENT Filing Doc
DEFA14A DEFINITIVE ADDITIONAL MATERIALS Filing Doc
424B3 PROSPECTUS Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K ANNUAL REPORT Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
424B5 PROSPECTUS SUPPLEMENT Filing Doc
8-K 5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$98.79M -$79.98M -$57.39M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $97.51M $45.8M $93.98M
Total non-current assets * $43,125 $21,975 $19,500
Total assets $97.55M $45.82M $94M
Total current liabilities $12.19M $10.29M $6.43M
Total non-current liabilities * $0M $0.004M $1.06M
Total equity $85.36M $35.52M $86.51M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$51.66M -$51.76M -$45.79M
Cash from investing $50.45M $51.56M -$48.14M
Cash from financing -$0.098M -$0.04M $93.56M
Net change in cash * -$1.3M -$0.235M -$0.36M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.